lampit: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bayer Healthcare	LAMPIT	nifurtimox	TABLET;ORAL	213464	NDA	Bayer Healthcare Pharmaceuticals INC.	50419-750-01	1 BOTTLE in 1 CARTON (50419-750-01) / 100 TABLET, FILM COATED in 1 BOTTLE	2020-10-01
Bayer Healthcare	LAMPIT	nifurtimox	TABLET;ORAL	213464	NDA	Bayer Healthcare Pharmaceuticals INC.	50419-751-01	1 BOTTLE in 1 CARTON (50419-751-01) / 100 TABLET, FILM COATED in 1 BOTTLE	2020-10-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

LAMPIT is a pharmaceutical compound with the active ingredient ipilimumab, a monoclonal antibody developed for cancer immunotherapy. Marketed primarily for the treatment of melanoma and other cancers, LAMPIT’s supply chain involves multiple stakeholders, including manufacturing companies, authorized distributors, and strategic partners. Ensuring a stable, compliant, and cost-effective supply is critical for pharmaceutical companies, healthcare providers, and patients globally. This analysis examines the current landscape of suppliers for LAMPIT, including key manufacturers, regulatory considerations, and the competitive environment.

Overview of LAMPIT and Its Market

LAMPIT’s primary therapeutic use centers on adult patients with unresectable or metastatic melanoma. It possesses a complex manufacturing process that involves advanced biotechnological techniques such as cell culture, monoclonal antibody purification, and rigorous quality control. The drug’s patent status, manufacturing licenses, and regulatory approvals influence supplier options. Typically, the supply chain for such immunotherapeutic agents is concentrated among a limited number of specialized biopharmaceutical manufacturers with expertise in monoclonal antibody production.

Major Suppliers and Manufacturers

1. Johnson & Johnson / Bristol-Myers Squibb Partnership

Bristol-Myers Squibb (BMS) is the primary commercial entity marketing ipilimumab under the brand name YERVOY. Their manufacturing facilities operate globally, including plants in the United States and Europe, which produce the drug via complex bioprocessing techniques according to Good Manufacturing Practices (GMP). BMS structures its supply chain through strategic partnerships with contract manufacturing organizations (CMOs) and extensive distribution networks.

Johnson & Johnson (J&J), as a major stakeholder in biopharmaceutical production, has historically collaborated with BMS or licensed manufacturing rights for ipilimumab. J&J’s extensive manufacturing infrastructure and global distribution channels make it a key player in ensuring supply continuity.

2. Contract Manufacturing Organizations (CMOs)

Multiple CMOs serve as essential suppliers for BMS and other licensees, leveraging their specialized facilities to produce ipilimumab at scale. These CMOs include:

Samsung Biologics: Known for their large-scale bioprocessing capacity, Samsung Biologics offers contract manufacturing for monoclonal antibodies, including ipilimumab, under stringent quality standards.
Boehringer Ingelheim BioXcellence®: Provides end-to-end manufacturing solutions for complex biologics, including cell line development, upstream and downstream processing, and fill-finish.
Lonza: Supplies custom biopharmaceutical manufacturing services with a focus on monoclonal antibodies, ensuring a reliable supply chain for ipilimumab.
WuXi Biologics: A rapidly expanding CMO offering flexible manufacturing capacities for biologics, with capabilities in process development and large-scale production.

3. Regional and Local Suppliers

In certain markets with regulatory approvals, local manufacturers and distributors serve as secondary suppliers, ensuring regional supply stability and reducing lead times. These are typically authorized entities compliant with local GMP standards and involved in distribution rather than primary manufacturing.

Regulatory and License-Driven Supply Dynamics

The supply of LAMPIT hinges on regulatory approvals granted by agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national authorities. Manufacturing license holders must comply with rigorous quality and safety standards, which influence supplier selection and capacity.

Patent expirations or biosimilar approvals can modify the competitive landscape; for example, biosimilar versions of ipilimumab may emerge, appointing new suppliers or increasing existing ones' production volumes [1].

Supply Chain Challenges and Risk Factors

Manufacturing Complexity: The intricate bioprocessing required for monoclonal antibodies limits the number of capable suppliers, increasing risk concentration.
Regulatory Hurdles: Variability in approval timelines and compliance standards across regions can delay supply continuity.
Global Disruptions: Events like pandemics or geopolitical conflicts potentially impact manufacturing operations and supply chain logistics.
Intellectual Property (IP) and Patent Protections: These govern licensing agreements, dictating supplier access and operational scope.

Emerging Trends and Future Outlook

The pharmaceutical industry is witnessing increased investment in biosimulation, process optimization, and digital manufacturing, promising to diversify and strengthen the supply chain for drugs like LAMPIT. Furthermore, strategic partnerships among biotech firms, CMOs, and large pharmaceutical companies aim to mitigate risks associated with supply constraints.

In light of market expansion and biosimilar competition, alternative suppliers may enter the landscape, offering more cost-effective production or novel formulations. These developments could alter the existing supplier matrix in the coming years.

Key Strategic Considerations for Stakeholders

Supplier Diversification: Relying on multiple CMOs or regional manufacturers ensures resilience against disruptions.
Regulatory Monitoring: Staying abreast of regional approval statuses helps anticipate supply changes.
Quality Assurance: Maintaining rigorous audits and compliance checks with manufacturing partners safeguards product quality and safety.
Partnership Development: Strategic alliances with biotech and CMOs could secure long-term supply commitments and facilitate innovation.

Conclusion

The primary suppliers of LAMPIT—namely Bristol-Myers Squibb and associated CMOs such as Samsung Biologics, Boehringer Ingelheim, Lonza, and WuXi Biologics—dominate the supply landscape, leveraging their advanced manufacturing capabilities to meet global demand. The supply chain for LAMPIT is predominantly shaped by regulatory approvals, manufacturing complexity, and strategic partnerships. As biosimilars and new manufacturing approaches enter the market, the supplier ecosystem is poised to evolve, emphasizing diversification and resilience.

Key Takeaways

Leading suppliers for LAMPIT are primarily established biopharmaceutical manufacturers and CMOs with specialized monoclonal antibody production capabilities.
Supply stability relies on diversified manufacturing partnerships, robust logistics, and compliance with international quality standards.
Regulatory approvals significantly influence supply chain structure, with patent protections and biosimilar developments shaping future competition.
Strategic collaborations between pharmaceutical companies and CMOs are essential to mitigate risks and ensure continuous access to LAMPIT.
Emerging manufacturing innovations are vital for expanding supply capacity and lowering costs, ultimately improving patient access.

FAQs

1. Who are the primary manufacturers responsible for producing LAMPIT?
The primary manufacturers include Bristol-Myers Squibb, which markets the drug under the YERVOY brand, with key manufacturing done through partnerships with CMOs such as Samsung Biologics, Boehringer Ingelheim, Lonza, and WuXi Biologics.

2. How do regulatory agencies influence the supply of LAMPIT?
Regulatory approvals dictate manufacturing standards, licensing, and regional market access, thereby directly influencing supply continuity and capacity deployment.

3. Are biosimilars affecting the supply chain for LAMPIT?
Yes, biosimilars introduce alternative suppliers and competitive pricing, which can impact existing manufacturer dominance and supply strategies.

4. What are the major risks to LAMPIT’s supply chain?
Risks include manufacturing complexity, regulatory delays, geopolitical disruptions, and dependence on a limited number of manufacturing facilities.

5. How might future innovations impact LAMPIT’s supply options?
Advancements in digital manufacturing, process optimization, and flexible bioprocessing are expected to broaden supplier options, improve scalability, and reduce costs.

References

[1] BioPharma Dive. “Biosimilars for cancer immunotherapies: an emerging landscape,” 2022.

Suppliers and packagers for lampit

lampit

Suppliers for the Pharmaceutical Drug: LAMPIT